PPIG and lactic acidosis: Ranolazine can inhibit CYP-mediated metabolism (CYP3A4) and/or transport proteins and thus lead to increased plasma levels of drug substrates and potential ADRs such as lactic acidosis when coadministered with metformin or myopathy and rhabdomyolysis with simvastatin [34,35].